Shang Hai Zheng Quan Bao·2025-06-13 20:34Core Viewpoint - The company, Junshi Biosciences, announced a placement of new H-shares to raise approximately HKD 1,039 million, aimed at strengthening its funding for long-term business development and enhancing its research capabilities in innovative drug development [15][18]. Group 1: Placement Agreement - The company entered into a placement agreement with an exclusive placing agent on June 12, 2025, to issue 41,000,000 new H-shares at a price of HKD 25.35 per share [2][3]. - The placement shares represent approximately 18.70% of the total issued H-shares and 4.16% of the total issued shares as of the announcement date [4]. Group 2: Use of Proceeds - The net proceeds from the placement are expected to be approximately HKD 1,026 million after deducting commissions and estimated expenses [15]. - The company plans to allocate 70% of the net proceeds to innovative drug research and development, including specific projects like JS207, JS212, and JS213, while the remaining 30% will be used for general corporate purposes [15]. Group 3: Conditions and Approval - The completion of the placement is subject to conditions, including approval from the Hong Kong Stock Exchange for the listing and trading of the placement shares [8][18]. - The company must also comply with the regulations of the China Securities Regulatory Commission and complete the necessary filings [18]. Group 4: Shareholder Impact - The placement is expected to optimize the company's capital structure by attracting high-quality investors, thereby enriching the shareholder base [15]. - The placement shares will rank equally with existing H-shares in all respects upon issuance [5].